List of Excipients in Branded Drug TARGRETIN

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
Bausch Health US LLC	TARGRETIN	bexarotene	0187-5525	ALCOHOL
Bausch Health US LLC	TARGRETIN	bexarotene	0187-5525	BUTYLATED HYDROXYTOLUENE
Bausch Health US LLC	TARGRETIN	bexarotene	0187-5525	HYDROXYPROPYL CELLULOSE
Bausch Health US LLC	TARGRETIN	bexarotene	0187-5525	POLYETHYLENE GLYCOL 400
Bausch Health US LLC	TARGRETIN	bexarotene	0187-5526	1,4-SORBITAN
Bausch Health US LLC	TARGRETIN	bexarotene	0187-5526	BUTYLATED HYDROXYANISOLE
Bausch Health US LLC	TARGRETIN	bexarotene	0187-5526	CROSPOVIDONE

TARGRETIN Excipient Strategy and Commercial Opportunities for Bexarotene

Last updated: August 20, 2026

TARGRETIN is the branded formulation of bexarotene, an oral retinoid X receptor agonist approved for cutaneous T-cell lymphoma (CTCL). Its commercial opportunity is concentrated in generic oral capsules, topical gel alternatives, excipient optimization, specialty-packaging services, and reformulations that reduce food-effect variability, gastrointestinal burden, skin irritation, and handling concerns. The strongest near-term opportunity is a compliant generic capsule with robust dissolution performance and reliable supply of lipid-solubilizing excipients.

What products and formulations does TARGRETIN contain?

TARGRETIN has two principal U.S. dosage forms: 75 mg oral capsules and 1% topical gel. The products have different excipient requirements and different competitive risks.

Product	Active ingredient	Strength	Route	Primary indication	FDA approval
TARGRETIN capsules	Bexarotene	75 mg	Oral	CTCL after failure of at least one prior systemic therapy	1999
TARGRETIN gel	Bexarotene	1%	Topical	Local treatment of cutaneous lesions in patients with CTCL	2000

The capsule is administered once daily with a meal. The prescribing information reports substantially higher bexarotene exposure when taken with a high-fat meal, making food-effect control a central formulation and labeling issue.[1]

The gel is applied to cutaneous lesions and is associated with local irritation, erythema, pruritus, and burning. Its excipient system must preserve bexarotene solubility while limiting evaporation, crystallization, and skin irritation.[2]

What excipients are used in TARGRETIN capsules?

The capsule formulation uses a solubilizing and wetting system built around:

• Polyethylene glycol 400
• Polysorbate 20
• Povidone
• Butylated hydroxyanisole
• Gelatin capsule shell components
• Colorants and opacifying agents, depending on the marketed presentation

Polyethylene glycol 400 functions as a liquid solvent and cosolvent. Polysorbate 20 supports wetting and dispersion. Povidone can improve drug distribution and physical stability. Butylated hydroxyanisole provides antioxidant protection.

This composition reflects the low aqueous solubility and lipophilic character of bexarotene. A generic developer should treat the formulation as a solubility and precipitation-control problem rather than as a simple powder-filled capsule.

What excipients are used in TARGRETIN gel?

The topical gel contains an alcohol-based vehicle with polyethylene glycol 400 and hydroxypropyl cellulose. The product also includes an antioxidant system.[2]

The vehicle is designed to dissolve bexarotene, spread across affected skin, and dry after application. Alcohol improves evaporation and can increase penetration, while polyethylene glycol 400 supports solubilization. Hydroxypropyl cellulose provides viscosity and helps maintain dose uniformity during application.

How strong is the excipient opportunity for generic TARGRETIN?

The oral capsule provides the more attractive generic opportunity because it has high technical barriers but a defined commercial need. The topical gel has a smaller patient population and more complex clinical-performance requirements.

Opportunity	Technical difficulty	Regulatory burden	Commercial attractiveness
75 mg oral capsule	Moderate to high	ANDA bioequivalence and CMC	High
1% topical gel	High	Product-specific topical equivalence requirements	Moderate
Lower-irritation topical gel	High	May require additional clinical or comparative data	Moderate
Lipid-based oral capsule	Moderate	Formulation and bioequivalence risk	High
Oral liquid or suspension	High	New dosage-form and stability burden	Low to moderate
Hospital or specialty pharmacy packaging	Low	Packaging and labeling compliance	Moderate
Excipient supply and contract manufacturing	Moderate	GMP and supply qualification	Moderate

Bexarotene is used in a specialty oncology setting, which supports premium generic pricing relative to high-volume primary-care drugs. Commercial success depends less on unit volume than on supply continuity, reimbursement access, pharmacy-channel reliability, and avoidance of product shortages.

What excipient strategy is best for a generic TARGRETIN capsule?

The preferred strategy is to reproduce the reference product’s performance using a simple, well-characterized solubilizing system unless a differentiated product has a clear regulatory or commercial advantage.

Strategy 1: Reference-like liquid or semisolid fill

A formulation based on polyethylene glycol 400, polysorbate 20, povidone, and antioxidant protection has the highest probability of matching the reference product’s dissolution and absorption behavior.

Key development targets include:

• Rapid and complete dispersion after capsule rupture
• Prevention of bexarotene precipitation in gastrointestinal media
• Stability under oxygen and light exposure
• Consistent fill weight and viscosity
• Compatibility with gelatin or an alternative capsule shell
• Low risk of capsule leakage or shell brittleness

The principal weakness is food-effect sensitivity. A reference-like formulation can satisfy bioequivalence requirements while retaining clinically meaningful exposure variability between fed and less-fed conditions.

Strategy 2: Lipid-based formulation

A self-emulsifying drug delivery system, or a related lipid-based system, could improve dispersion and reduce dependence on meal composition. Candidate excipient classes include medium-chain triglycerides, mono- and diglycerides, nonionic surfactants, and hydrophilic cosolvents.

The commercial value would come from more consistent exposure, not necessarily from a new label claim. The development risk is higher because changes in lipid composition can alter absorption and may trigger more complex bioequivalence questions.

A lipid-based approach should be evaluated against:

• Fed and fasted pharmacokinetics
• Particle-size distribution after dilution
• Precipitation during gastrointestinal transit
• Oxidative stability
• Capsule-shell compatibility
• Food-effect magnitude
• Storage at elevated temperature and humidity

Strategy 3: Solid dispersion or amorphous formulation

A spray-dried dispersion or hot-melt system could increase apparent solubility. Povidone, copovidone, hydroxypropyl cellulose, or hypromellose acetate succinate may be considered as polymeric carriers.

This approach may reduce the need for large amounts of liquid excipient, but it introduces risks of recrystallization, residual solvent, hygroscopicity, and manufacturing-cost escalation. It is more suitable for a lifecycle product than for the lowest-cost first generic.

Strategy 4: Capsule-shell redesign

A hard gelatin capsule is the lowest-risk presentation. Hypromellose or pullulan shells may offer advantages in vegetarian markets, moisture control, and supply diversification.

Shell substitution must be assessed for:

• Drug migration into the shell
• Moisture transfer
• Mechanical strength
• Dissolution timing
• Colorant compatibility
• Printing and serialization
• Stability under distribution conditions

A shell change alone is unlikely to create a meaningful commercial premium unless it solves a documented stability or supply problem.

What formulation patents and regulatory protections affect TARGRETIN?

The original bexarotene composition and use patents are old, and the primary market exclusivity periods for the approved CTCL indications have expired. TARGRETIN’s key regulatory protections were orphan-drug exclusivity periods associated with its CTCL approvals. The seven-year orphan exclusivity periods would have ended approximately seven years after the respective approvals, subject to the precise orphan designation and approval dates.[1][2]

The relevant commercial barriers now arise mainly from:

• Product-specific bioequivalence requirements
• Formulation complexity
• Manufacturing reproducibility
• Specialty distribution
• Limited patient volume
• Pharmacovigilance and labeling obligations
• Potential patent protection on later-developed formulations, if any

The FDA Orange Book should be used to confirm current patent listings for the applicable reference product and dosage form. Older compound and use patents should not be treated as a current barrier without reviewing their expiration, terminal disclaimers, pediatric extensions, reexamination history, and any later-listed formulation patents.[3]

Are there Paragraph IV risks for TARGRETIN?

A generic applicant could use an ANDA with Paragraph IV certification if an applicable Orange Book patent remained listed and the applicant asserted noninfringement, invalidity, or unenforceability. If no unexpired listed patent blocks approval, the applicant could rely on a Paragraph III certification or submit without a listed-patent challenge, depending on the current Orange Book record.[3]

For a mature product such as TARGRETIN, the greater risk is often commercial rather than patent litigation. A first filer may face limited market depth, while later filers may enter a price-sensitive specialty market with low switching costs among generic products.

What FDA regulatory pathway applies to TARGRETIN generics?

The conventional pathway is an ANDA for a generic version of the capsule or gel. FDA review focuses on pharmaceutical equivalence, bioequivalence, manufacturing controls, and labeling.

Oral capsule requirements

A generic capsule developer should expect work in the following areas:

• Comparative dissolution across multiple media
• Assay and content uniformity
• Impurity and degradation-product control
• Fed and fasted bioequivalence
• Stability under ICH conditions
• Extractables and leachables assessment
• Capsule-shell compatibility
• Container-closure protection from light and moisture

Because bexarotene has a large food effect, the fed study design is especially important. A product that matches exposure under one condition but diverges under another creates approval and post-launch substitution risk.

Topical gel requirements

The topical product presents a more demanding equivalence problem. A developer may need comparative assessment of:

• Q1 qualitative sameness
• Q2 quantitative sameness
• Rheology
• Adhesion and spreadability
• Drying time
• Drug release
• Skin permeation
• Microscopic particle or crystal behavior
• Irritation and sensitization potential

FDA’s evolving topical-product guidance supports in vitro comparative approaches in some circumstances, but the exact evidence package depends on the dosage form and product-specific guidance.[4]

What commercial opportunities exist beyond a standard generic?

Lower-irritation topical product

Local irritation is a recognized limitation of retinoid therapy. A gel using a lower-evaporation vehicle, alternative solvent balance, or improved humectant system could target better tolerability.

The challenge is maintaining bexarotene solubility without increasing systemic exposure or reducing local delivery. A lower-irritation product may require a 505(b)(2) pathway rather than a conventional ANDA if it is not qualitatively and quantitatively equivalent to the reference gel.

Specialty pharmacy packaging

Bexarotene labeling contains important warnings involving hyperlipidemia, thyroid abnormalities, pancreatitis, liver toxicity, and drug interactions.[1] Packaging and pharmacy-support services can create value through:

• Treatment-start checklists
• Laboratory-monitoring reminders
• Unit-of-use cartons
• Light- and moisture-protective packaging
• Medication guides
• Refill coordination for oncology practices

These services do not create exclusivity but can improve formulary acceptance and persistence.

Contract manufacturing and excipient supply

The formulation depends on excipients with pharmaceutical-grade consistency. Suppliers can compete through:

• Low-peroxide polyethylene glycol 400
• Consistent polysorbate quality
• Antioxidant-stabilized excipient blends
• Prequalified liquid-fill systems
• Capsule-shell supply redundancy
• Small-batch specialty manufacturing

For a low-volume oncology product, supply disruption can have a disproportionate commercial effect. A manufacturer that offers validated secondary sourcing may win contracts even without the lowest unit price.

Reformulated oral products

A new oral formulation could target:

• Reduced food-effect variability
• Lower dose volume
• Improved swallowability
• Greater chemical stability
• Reduced capsule leakage
• More predictable exposure

The strongest lifecycle case is a formulation with a measurable pharmacokinetic or adherence advantage. A cosmetic excipient change is unlikely to justify a premium or a new regulatory pathway.

How does TARGRETIN compare with competing CTCL treatments?

TARGRETIN competes with other systemic and skin-directed CTCL treatments, including bexarotene alternatives, extracorporeal photopheresis, interferon-based regimens, histone deacetylase inhibitors, antibody-drug conjugates, and newer targeted therapies.

Treatment category	Main commercial advantage	Excipient opportunity
Oral bexarotene	Established systemic retinoid option	Solubility, food-effect, and capsule stability
Topical bexarotene	Local treatment for limited lesions	Irritation reduction and improved spreadability
HDAC inhibitors	Systemic activity in advanced disease	Conventional oral solid-dose optimization
Biologic therapies	Targeted treatment and specialty pricing	Low biosimilar relevance for small molecules
Photopheresis	Non-oral treatment pathway	Device and procedural, not excipient, differentiation

Biosimilar risk is not material for TARGRETIN because bexarotene is a synthetic small molecule, not a biologic. The relevant competitors are generics, reformulated products, and alternative CTCL therapies.

When does TARGRETIN lose exclusivity?

TARGRETIN’s original orphan-drug exclusivity periods expired years ago. The capsule was approved in 1999 and the gel in 2000, making the corresponding seven-year orphan periods approximately 2006 and 2007, respectively, subject to the exact designation and approval records.[1][2]

The practical market-entry question is therefore whether current Orange Book patents, regulatory exclusivity, or product-specific approval requirements remain. For a mature bexarotene product, excipient and manufacturing execution are more likely to determine launch timing than basic molecule exclusivity.

What patent litigation or settlement issues affect TARGRETIN?

Publicly important risk centers on any current Orange Book-listed patent and the associated ANDA litigation record. A developer should distinguish among:

1. Original bexarotene compound patents.
2. CTCL method-of-use patents.
3. Formulation or dosage-form patents.
4. Manufacturing-process patents.
5. Later patents covering lipid systems, topical vehicles, or controlled release.

Expired composition and method patents do not create a current launch barrier. Later formulation patents can matter if they are listed and enforceable, but a formulation patent does not automatically prevent an ANDA directed to a different, noninfringing formulation.

No biosimilar settlement framework applies. Any generic settlement would be evaluated under the Hatch-Waxman framework and could involve entry dates, patent licenses, supply arrangements, or authorized-generic commitments. The Federal Trade Commission and FDA records are the principal sources for identifying such agreements.[3][5]

What geographic opportunities exist for TARGRETIN excipients and generics?

The United States is the clearest regulated opportunity because the FDA reference product, Orange Book, and ANDA pathway provide a defined approval framework. Europe and other markets require separate assessment of national or regional marketing authorizations, reference-product status, and local CTCL treatment patterns.

Geographic priorities are:

• United States: generic capsule and specialty-pharmacy supply
• European Union: national or centralized regulatory assessment, depending on product status
• Canada: small specialty market with potential supply opportunities
• Japan: local regulatory and clinical requirements
• Emerging markets: lower price levels but greater need for stable, affordable oncology supply

Excipient suppliers can pursue global opportunities even when product-level generic approval is limited. Pharmaceutical-grade PEG 400, polysorbate systems, cellulose polymers, capsule shells, and antioxidants have broader applications across oral and topical drug products.

Key Takeaways

• TARGRETIN is bexarotene, marketed as a 75 mg oral capsule and 1% topical gel.
• The capsule’s main technical challenge is poor solubility combined with a clinically significant food effect.
• A reference-like PEG 400, polysorbate 20, povidone, and antioxidant system is the lowest-risk generic formulation strategy.
• Lipid-based and amorphous-dispersion formulations offer stronger differentiation but carry higher bioequivalence and manufacturing risk.
• The topical gel opportunity is centered on reducing irritation while preserving drug release and skin permeation.
• Original orphan exclusivity periods have expired; current entry analysis should focus on the Orange Book, ANDA requirements, formulation patents, and manufacturing capability.
• Bexarotene has no biosimilar risk because it is a synthetic small molecule.
• Commercial value is concentrated in reliable specialty supply, formulation robustness, packaging, and pharmacy-channel execution.

FAQs About TARGRETIN Excipient and Commercial Strategy

What is the best generic formulation approach for TARGRETIN capsules?

A reference-like liquid or semisolid capsule using PEG 400, polysorbate 20, povidone, and antioxidant protection is the most direct approach. A lipid-based system is more differentiated but requires stronger control of fed and fasted pharmacokinetics.

Can a company launch a new TARGRETIN topical gel through an ANDA?

Only if the product meets FDA requirements for pharmaceutical equivalence and bioequivalence to the reference gel. Meaningful changes to the vehicle, solvent system, or delivery profile may require a 505(b)(2) application.

Does TARGRETIN have biosimilar competition?

No. Bexarotene is a small-molecule active ingredient. Competition comes from generic capsules, topical alternatives, reformulations, and other CTCL therapies.

Which excipient is most important for bexarotene solubility?

PEG 400 is a primary solvent in the capsule formulation, while polysorbate 20 supports wetting and dispersion. The performance of the combined system is more important than any single excipient.

What is the largest commercial risk for a TARGRETIN generic?

The largest risk is limited specialty-market volume combined with formulation and supply-chain complexity. A technically approvable product may still underperform if it lacks reliable oncology distribution, reimbursement access, and stable excipient supply.

References

1. U.S. Food and Drug Administration. (n.d.). Targretin (bexarotene) capsules prescribing information. FDA/DailyMed.

2. U.S. Food and Drug Administration. (n.d.). Targretin (bexarotene) gel prescribing information. FDA/DailyMed.

3. U.S. Food and Drug Administration. (n.d.). Approved drug products with therapeutic equivalence evaluations: Orange Book. https://www.accessdata.fda.gov/scripts/cder/ob/

4. U.S. Food and Drug Administration. (2022). Physiologically based pharmacokinetic analyses for topical products submitted in ANDAs. FDA guidance.

5. Federal Trade Commission. (n.d.). Agreements filed with the Federal Trade Commission under the Medicare Prescription Drug, Improvement, and Modernization Act. https://www.ftc.gov/plusalisting-tests/agreements-filed-under-medicare-prescription-drug-improvement-modernization-act?_flex_fields_department_target_id=All&_flex_fields_enforcement_type_target_id=All&_flex_fields_matter_status_target_id=All&_flex_fields_date_value=All&_flex_fields_date_value_1=All&_flex_fields_matter_title_value=All&page=0